Last reviewed · How we verify

SpyGlass Pharma, Inc. — Portfolio Competitive Intelligence Brief

SpyGlass Pharma, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bimatoprost Implant System Bimatoprost Implant System phase 3 Prostaglandin F analog Prostaglandin F (FP) receptor Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Ahmed Hassan Nouh MD · 1 shared drug class
  3. Allergan · 1 shared drug class
  4. Association for Innovation and Biomedical Research on Light and Image · 1 shared drug class
  5. CHU de Quebec-Universite Laval · 1 shared drug class
  6. Dr. David Yan · 1 shared drug class
  7. Kasr El Aini Hospital · 1 shared drug class
  8. Merck Sharp & Dohme LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for SpyGlass Pharma, Inc.:

Cite this brief

Drug Landscape (2026). SpyGlass Pharma, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/spyglass-pharma-inc. Accessed 2026-05-16.

Related